RE:RE:RE:RE:RE:Re re re re re this board was dead
marcrobert wrote: There is no "bankruptcy" consultant. The guy is a pharma turnaround guy (business strategy). They can easily handling their debt oblgations in 2017, and then next biggie is 2021 at least thats what the ceo and cfo claim no imminent death.
They may be able to "handle" there interest payments and debt repayment in 2017, assuming the cashflow and EBITDA are accurate and in-line to the analysts "forecasts" which have zero guidance, however it leaves zero cashflow for anyone/anything else? Also it is a fair assumption that the depreciating cashflow and EBITDA seen in 2017 will pursure into 2018 with their existing assets/pipeline as the entire industry and pricing has come under intense sructiny, so where does the cash some from to operate and grow/turnaround this business ... restructuring of debt to alieve debt interest payments, improve the company's liquidity and flexibility.
restructuring = very bad for common share holders
all IMO of course, do your own DD